AlphAIAlphAI — Financial news for AI agents
gizmodo.comOCT 233 min read$MRK

These Melanoma Patients Got a Vaccine Made for Their Own Tumors. 2 Years Later, 82% Are Still Cancer-Free

Merck and Moderna's personalized melanoma vaccine, intismeran, showed promising Phase III results, reducing cancer recurrence or death by 42% after two years. 82.2% of vaccinated patients were cancer-free compared to 70% on Keytruda alone. The companies plan to publish findings in the New England Journal of Medicine and seek regulatory approval.

Original reporting
gizmodo.com
Published Oct 23, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 2:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
These Melanoma Patients Got a Vaccine Made for Their Own Tumors. 2 Years Later, 82% Are Still Cancer-Free — source image
Source · gizmodo.com
Decision brief

The 30-second read

$MRKBullishHigh
01

Why it matters

The data shows a 42% reduction in recurrence risk and 82% cancer‑free rate at two years, suggesting a strong commercial opportunity.

02

Market read

First‑time disclosure of pivotal oncology trial results likely to move both stocks and the broader biotech sector.

03

What to watch

Potential safety concerns, manufacturing scale‑up costs, and competition from other cancer vaccine programs.

Relevance 9/10Novelty 9/10Timing: today's market reaction

Background

The article reports the first public release of Phase III trial data for intismeran, a personalized mRNA melanoma vaccine co‑developed by Merck and Moderna.

Company-level read

Ticker impact

$MRKBullishHigh confidence
Context

Merck co‑developed the intismeran melanoma vaccine; Phase III data showing 42% lower recurrence risk was released for the first time.

Expected impact

likely upward pressure as investors price in potential regulatory approval and future sales

Evidence & confidence

First‑time disclosure of pivotal Phase III results; market expects a new product line and revenue uplift.

$MRNABullishHigh confidence
Context

Moderna partnered with Merck on the intismeran vaccine; the same Phase III results were released, indicating strong efficacy.

Expected impact

upward pressure as the data validates Moderna's mRNA platform beyond infectious disease

Evidence & confidence

First disclosure of pivotal trial outcomes; validates pipeline and could accelerate future oncology collaborations.

Market effects

Sector

Strengthens the oncology and mRNA vaccine subsectors, may lift peer biotech stocks.

Regional

U.S. biotech sector could see a modest gain.

Global

Highlights the potential of mRNA technology for cancer, relevant to global pharma investors.

Counterpoint

What could challenge this read

Skeptics may question long‑term durability of response and regulatory timeline.

Key entities

  • company
    Merck

    Co‑developer of the intismeran vaccine; US‑listed under MRK.

  • company
    Moderna

    Co‑developer of the intismeran vaccine; US‑listed under MRNA.

Read at source← All news

StoryMerck and Moderna report positive Phase 3 melanoma vaccine results after data leak

Also covered by

6 outlets

Related articles

OCT 23
$MRNALowAI 8/10

Why is Moderna stock sliding today?

Moderna's stock fell 2.3% after early release of Phase 3 trial data for its melanoma vaccine showed a 42% risk reduction, below prior expectations. Analysts reacted with mixed views, and the stock is down from its 52-week high. The broader market and sector peers are largely unaffected.

investing.com2 min
OCT 23
$MRNAMed

Moderna stock extends decline after leaked data on melanoma vaccine trial

Moderna (MRNA) stock fell 2% on Friday, extending a 17% drop from Thursday, after leaked data from a late-stage melanoma vaccine trial disappointed investors. The trial was conducted with Merck (MRK). Goldman Sachs (GS) raised its target to $137, while Morgan Stanley (MS) and Citi (C) maintain Neutral and Sell ratings, respectively. The stock is down from $200 despite positive Phase 3 results in August.

finance.yahoo.com2 min
OCT 23
$MRNAMed

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Moderna (MRNA) shares fell 4% to $193.62, extending an 18% drop, after full late-stage results for its melanoma vaccine with Merck (MRK) were released. The data met expectations but fell short of high hopes, triggering a correction. Moderna's stock is more exposed due to its focus on oncology, while Merck's stock declined 0.8% to $146. Pfizer (PFE) also saw a minor decline of 0.7% to $30.22.

247wallst.com2 min
OCT 23
$MRNAHighAI 8/10

Moderna Stock Cools After Cancer Vaccine Data Leak

Moderna (MRNA) stock fell 3.9% premarket after a 17% drop yesterday. The decline followed a data leak on its cancer vaccine with Merck (MRK), which showed a 42% reduction in recurrence or death risk in phase 3 trials. The stock hit a four-year high of $254.48 on Oct. 21 and is up 587% year-to-date. Bearish bets on MRNA have increased, with a high put/call ratio.

schaeffersresearch.com1 min
OCT 23
$MRNAHigh

Moderna & Merck Cancer Vaccine Succeeds, Shares Retreat

Moderna and Merck reported that their personalized mRNA cancer vaccine, combined with Keytruda, reduced melanoma risk by 42% in a Phase 3 trial. The vaccine is tailored to individual tumor mutations. Shares of both companies fell despite positive results, with Moderna down 17% and Merck down 1.8%. The companies plan to seek U.S. approval and expect to introduce the vaccine in 2027.

tradingpedia.com3 min